Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Free Cash Flow (2016 - 2025)

Dare Bioscience (DARE) has disclosed Free Cash Flow for 11 consecutive years, with -$290576.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow rose 94.85% year-over-year to -$290576.0, compared with a TTM value of -$6.8 million through Sep 2025, up 14.5%, and an annual FY2024 reading of $4.8 million, up 112.42% over the prior year.
  • Free Cash Flow was -$290576.0 for Q3 2025 at Dare Bioscience, up from -$5.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $12.6 million in Q2 2024 and bottomed at -$16.1 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$4.9 million, with a median of -$6.6 million recorded in 2023.
  • The sharpest move saw Free Cash Flow soared 554.4% in 2022, then tumbled 193.57% in 2023.
  • Year by year, Free Cash Flow stood at -$9.9 million in 2021, then soared by 40.51% to -$5.9 million in 2022, then tumbled by 38.27% to -$8.2 million in 2023, then soared by 157.25% to $4.7 million in 2024, then crashed by 106.22% to -$290576.0 in 2025.
  • Business Quant data shows Free Cash Flow for DARE at -$290576.0 in Q3 2025, -$5.6 million in Q2 2025, and -$5.6 million in Q1 2025.